Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.
作者信息
Jayasekera Jinani, Mandelblatt Jeanne S
机构信息
Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
出版信息
J Clin Oncol. 2020 Feb 1;38(4):332-350. doi: 10.1200/JCO.19.01525. Epub 2019 Dec 5.
Abstract
摘要
相似文献
1
Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.
J Clin Oncol. 2020 Feb 1;38(4):332-350. doi: 10.1200/JCO.19.01525. Epub 2019 Dec 5.
2
A quest for quality and economic effectiveness throughout the continuum of breast care.
Breast. 2010 Aug;19(4):251-2. doi: 10.1016/j.breast.2010.03.020. Epub 2010 Apr 13.
3
Is mammography for breast cancer screening cost-effective in both Western and asian countries?: results of a systematic review.
Asian Pac J Cancer Prev. 2013;14(7):4141-9. doi: 10.7314/apjcp.2013.14.7.4141.
4
Cost-effectiveness analysis of mammography screening in Hong Kong Chinese using state-transition Markov modelling.
Hong Kong Med J. 2010 Jun;16 Suppl 3:38-41.
5
Economic Evaluation of Breast Cancer Early Detection Strategies in Asia: A Systematic Review.
Value Health Reg Issues. 2020 May;21:252-263. doi: 10.1016/j.vhri.2020.01.003. Epub 2020 May 6.
6
Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening.
Radiol Clin North Am. 2010 Sep;48(5):879-91. doi: 10.1016/j.rcl.2010.06.002.
7
Costs of breast cancer and the cost-effectiveness of breast cancer screening.
Int J Technol Assess Health Care. 1991;7(4):604-15. doi: 10.1017/s0266462300007169.
8
Cost-effectiveness of Leveraging Social Determinants of Health to Improve Breast, Cervical, and Colorectal Cancer Screening: A Systematic Review.
JAMA Oncol. 2020 Sep 1;6(9):1434-1444. doi: 10.1001/jamaoncol.2020.1460.
9
Cost-effectiveness of risk-based breast cancer screening programme, China.
Bull World Health Organ. 2018 Aug 1;96(8):568-577. doi: 10.2471/BLT.18.207944. Epub 2018 Jun 28.
10
Economics of Multicomponent Interventions to Increase Breast, Cervical, and Colorectal Cancer Screening: A Community Guide Systematic Review.
Am J Prev Med. 2019 Oct;57(4):557-567. doi: 10.1016/j.amepre.2019.03.006. Epub 2019 Aug 30.
引用本文的文献
1
A comprehensive epidemiological analysis of breast cancer in the Eastern Province of Saudi Arabia.
Sci Rep. 2025 Jul 1;15(1):20816. doi: 10.1038/s41598-025-05276-7.
2
Cost-effectiveness of expanding the target population of biennial screening for breast cancer from ages 50-69 to 45 and/or 74: A cohort modelling study in the Finnish setting.
Health Econ Rev. 2025 Apr 11;15(1):35. doi: 10.1186/s13561-025-00628-5.
3
Molecular Docking and Pharmacological In Silico Evaluation of Camptothecin and Related Ligands as Promising HER2-Targeted Therapies for Breast Cancer.
Curr Issues Mol Biol. 2025 Mar 15;47(3):193. doi: 10.3390/cimb47030193.
4
The Future of Breast Cancer Organized Screening Program Through Artificial Intelligence: A Scoping Review.
Healthcare (Basel). 2025 Feb 10;13(4):378. doi: 10.3390/healthcare13040378.
5
Cost-Effectiveness of Breast Cancer Screening Using Digital Mammography in Canada.
JAMA Netw Open. 2025 Jan 2;8(1):e2452821. doi: 10.1001/jamanetworkopen.2024.52821.
6
Health utilities used in oncology cost-utility analyses: a registry-based analysis.
Qual Life Res. 2025 Mar;34(3):801-807. doi: 10.1007/s11136-024-03856-0. Epub 2024 Nov 27.
7
Budget impact analysis of introducing digital breast tomosynthesis in breast cancer screening in Italy.
Radiol Med. 2024 Sep;129(9):1288-1302. doi: 10.1007/s11547-024-01850-7. Epub 2024 Aug 20.
8
Evaluation of Financial Interventions in Breast Cancer Care Worldwide: A Systematic Review.
Plast Reconstr Surg Glob Open. 2024 May 23;12(5):e5683. doi: 10.1097/GOX.0000000000005683. eCollection 2024 May.
9
Anastrozole for the prevention of breast cancer in high-risk postmenopausal women: cost-effectiveness analysis in the UK and the USA.
BMC Health Serv Res. 2024 Feb 13;24(1):198. doi: 10.1186/s12913-024-10658-0.
10
Critical assessment of resource waste in staging and follow-up of breast cancer.
Rev Assoc Med Bras (1992). 2023 Nov 24;69(12):e20230565. doi: 10.1590/1806-9282.20230565. eCollection 2023.
本文引用的文献
1
Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study.
Eur J Breast Health. 2019 Jul 1;15(3):183-190. doi: 10.5152/ejbh.2019.4761. eCollection 2019 Jul.
2
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.
PLoS One. 2019 Jun 5;14(6):e0217778. doi: 10.1371/journal.pone.0217778. eCollection 2019.
3
Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
Pharmacogenomics J. 2020 Feb;20(1):27-46. doi: 10.1038/s41397-019-0089-x. Epub 2019 May 27.
4
Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR/HER2 Metastatic Breast Cancer From the US and Chinese Perspectives.
Clin Ther. 2019 Jun;41(6):1175-1185. doi: 10.1016/j.clinthera.2019.04.033. Epub 2019 May 17.
5
Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program.
Cancer Causes Control. 2019 Aug;30(8):819-826. doi: 10.1007/s10552-019-01178-y. Epub 2019 May 16.
6
Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK.
Pharmacoecon Open. 2019 Dec;3(4):559-570. doi: 10.1007/s41669-019-0134-3.
7
Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Value Health. 2019 Apr;22(4):408-415. doi: 10.1016/j.jval.2018.11.014. Epub 2019 Mar 11.
8
Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Breast. 2019 Jun;45:82-88. doi: 10.1016/j.breast.2019.03.004. Epub 2019 Mar 12.
9
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
Breast Cancer Res Treat. 2019 Jun;175(3):775-779. doi: 10.1007/s10549-019-05190-3. Epub 2019 Mar 7.
10
Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Eur J Health Econ. 2019 Jul;20(5):739-750. doi: 10.1007/s10198-019-01038-1. Epub 2019 Feb 21.
Zotero 插件